Pharvaris (NASDAQ:PHVS) Stock Price Breaks Below 50-Day Moving Average - Should You Sell?

Pharvaris logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Pharvaris shares fell below their 50-day moving average, trading as low as $32.44 versus the average of $33.19.
  • Analyst sentiment remains broadly positive: 14 analysts rate the stock Buy and one rates it Sell, with a consensus “Moderate Buy” rating and an average price target of $59.53.
  • The company reported a quarterly loss of $0.77 per share, beating the $0.81 loss analysts expected; meanwhile, insiders sold 510,810 shares worth about $18.6 million over the past 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shares passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $33.19 and traded as low as $32.44. Pharvaris shares last traded at $32.44, with a volume of 307,769 shares.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PHVS shares. Wedbush boosted their target price on Pharvaris from $42.00 to $50.00 and gave the stock an "outperform" rating in a report on Wednesday, September 9th. Wells Fargo & Company upped their target price on Pharvaris from $55.00 to $65.00 and gave the company an "overweight" rating in a report on Wednesday, September 9th. Guggenheim raised their target price on Pharvaris from $40.00 to $44.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. HC Wainwright reiterated a "buy" rating on shares of Pharvaris in a report on Tuesday, October 6th. Finally, Oppenheimer reissued an "outperform" rating on shares of Pharvaris in a research report on Friday, October 23rd. Fourteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris has a consensus rating of "Moderate Buy" and an average target price of $59.53.

Get Our Latest Stock Analysis on Pharvaris

Pharvaris Stock Down 2.8%

The firm has a 50-day moving average of $33.19 and a two-hundred day moving average of $31.34. The company has a market capitalization of $2.12 billion, a PE ratio of -10.40 and a beta of -2.48.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.04. On average, equities research analysts expect that Pharvaris N.V. will post -3.02 EPS for the current year.

Insiders Place Their Bets

In related news, Director Johannes Gerardus Chri Schikan sold 200,000 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total transaction of $7,000,000.00. Following the completion of the sale, the director owned 115,167 shares in the company, valued at $4,030,845. This represents a 63.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elisabeth Bjork sold 52,500 shares of the business's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $37.89, for a total value of $1,989,225.00. Following the completion of the transaction, the director owned 15,167 shares in the company, valued at $574,677.63. This trade represents a 77.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 510,810 shares of company stock worth $18,563,973.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new position in shares of Pharvaris in the 2nd quarter valued at about $41,000. CoreCap Advisors LLC purchased a new stake in Pharvaris during the second quarter worth about $93,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris during the third quarter worth about $114,000. Public Employees Retirement System of Ohio acquired a new position in Pharvaris during the second quarter worth about $196,000. Finally, Algert Global LLC acquired a new position in Pharvaris during the second quarter worth about $238,000.

Pharvaris Company Profile

(Get Free Report)

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pharvaris Right Now?

Before you consider Pharvaris, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.

While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines